Eli Lilly and Co. received approval from the U.S. FDA for CYRAMZA (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) and have been treated with sorafenib. Concurrent with this FDA approval – the fifth for CYRAMZA – the FDA has also removed the boxed warning from the CYRAMZA labeling. HCC is the most common form of liver cancer, which is the fourth-leading cause of cancer-related d...